# Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

> **NCT04263090** · PHASE1,PHASE2 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 25 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Adenocarcinoma
- Stage IV

## Interventions

- **DRUG:** Rigosertib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04263090
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-29
- **Primary completion:** 2023-12-20
- **Final completion:** 2023-12-20
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04263090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04263090, "Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04263090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*